Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
Jaguar Health (NASDAQ: JAGX) has announced that it has regained compliance with Nasdaq's bid price requirement as of June 25, 2024, ensuring its securities remain listed and traded on Nasdaq. The company is also set to report results from its pivotal phase 3 OnTarget trial for the cancer supportive care drug crofelemer by July 23, 2024. Jaguar's CEO, Lisa Conte, emphasized the importance of maintaining their Nasdaq listing and mentioned an upcoming investor webcast that will discuss Jaguar's cancer supportive care portfolio, featuring insights from scientific experts and patient advocates.
- Jaguar Health has regained compliance with Nasdaq's minimum bid price requirement.
- Upcoming pivotal phase 3 OnTarget trial results for crofelemer by July 23, 2024, could be significant for the company's cancer supportive care portfolio.
- None.
Insights
Regaining compliance with Nasdaq's minimum bid price requirement is a noteworthy achievement for Jaguar Health (JAGX). This compliance is important because it prevents the company from being delisted, which could have had negative impacts on investor confidence and stock liquidity. The Nasdaq listing offers Jaguar Health substantial visibility and credibility among investors.
Maintaining the Nasdaq listing also facilitates Jaguar's access to capital markets, providing opportunities for future fundraising through equity offerings. This is particularly significant for a biotech company often in need of consistent funding for ongoing research and development. Investors should take into account that while this news stabilizes Jaguar's position in the short-term, the long-term success largely depends on the outcomes of the company's ongoing clinical trials and product pipeline developments.
Jaguar Health's upcoming Phase 3 OnTarget trial results for crofelemer, aimed at treating cancer therapy-related conditions like CTD and oral mucositis, are another critical element of this announcement. These conditions are significant issues for cancer patients, often leading to interruptions in treatment. Successful trial outcomes could lead to FDA approval, providing a new supportive care option that would meet a substantial unmet medical need.
The OnTarget trial's results will be pivotal; positive results could not only enhance Jaguar's product portfolio but also boost investor confidence by validating the scientific foundation of their research. However, investors should remain cautious, as clinical trial outcomes can be unpredictable and the regulatory pathway to approval can be lengthy and complex.
JAGX's securities continue to be listed and traded on Nasdaq
Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024
SAN FRANCISCO, CA / ACCESSWIRE / June 26, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on June 25, 2024 the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that Jaguar has regained compliance with Nasdaq's minimum bid price requirement.
"We are very happy that Jaguar has regained compliance with Nasdaq. We consider our Nasdaq listing an asset of the Company," said Lisa Conte, Jaguar's president and CEO. "A Jaguar investor webcast held on or before July 23, 2024 will provide updates on Jaguar's advancing cancer supportive care portfolio, and will include members of Jaguar's scientific team, patient advocates, and leading oncology experts on two of the most common and intolerable side effects of cancer therapy: CTD and oral mucositis."
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Crofelemer also is the subject of Napo's phase 3 OnTarget clinical trial for preventive treatment of cancer therapy-related diarrhea (CTD). Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program at makecancerlessshitty.com and on X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar will report the results of the OnTarget trial on or before July 23, 2024, and the expectation that Jaguar will hold an investor webcast on or before July 23, 2024 regarding updates on the Company's cancer supportive care portfolio. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health
View the original press release on accesswire.com
FAQ
What recent compliance update did Jaguar Health receive from Nasdaq?
What is significant about July 23, 2024, for Jaguar Health?
What is the ticker symbol for Jaguar Health?
What will the upcoming Jaguar Health investor webcast cover?
